Objective: The aim of this study is to evaluate the efficacy of dipyridamole in relieving the vasospasm of coronary artery bypass grafts.
Introduction
The importance of coronary artery bypass grafting (CABG) and the different types of grafts consequently has increased due to a rising incidence of cardiovascular diseases. In CABG, myocardial ischemia is relieved by the use of grafts resulting in a higher quality of life in patients. The internal mammary artery (IMA), radial artery (RA) and saphenous vein (SV) grafts are the most frequently used grafts for this purpose (1) (2) (3) . The choice and preparation of the optimum graft is critical in the long term graft patency. Mechanical trauma or the pharmacological agents used during the preparation of the graft are known to have a negative impact on long term graft patency (1-3). Several studies have addressed the ways to prevent spasm of arterial or venous grafts. Vasodilators like papaverin, diltiazem and nitroglycerine are widely used for this purpose but the data on the efficacy of dipyridamole is very limited.
Dipyridamole, which was first introduced 50 years ago as a coronary vasodilator, increases interstitial adenosine concentration by blocking adenosine uptake and relieves ischemia. It is widely used in coronary and peripheral arterial disease, restenosis and stroke (4).
The aim of this study is to evaluate the efficacy of dipyridamole in relieving vasospasm of coronary artery bypass grafts under in vitro conditions.
Material and Methods

Graft Sampling
Twenty two patients (14 men and 8 women) were included in the study after the approval of the local ethics committee. The mean age was 62.4±8.8 (42-77) years. Ten samples were studied for LIMA, RA and SV grafts each. In total, 30 vessel samples were studied in an organ bath setting.
Organ Bath
The LIMA and RA grafts were collected together with the adjacent vein, fascia and adipose tissue with the aid of dissection scissors. The graft tissues were not exposed to any vasodilator drug. The SV samples were collected without being inflated to prevent barotrauma. The samples were transported to the vascular laboratory in 4ºC Krebs solution, which contained (mM) NaCl 122, KCl 5, CaCl 2 1.25, NaHCO 3 25, MgSO 4 1.2, KH 2 PO 4 1.0, glucose 11.5. Ten mililiters of solution found in the tissue bath was continously oxygenated by 95% O 2 and 5% CO 2 . The grafts were dissected from the adjacent tissues and was sliced into 3mm width vascular rings under the microscope. The vascular rings were suspended into the classical tissue bath system via steel hooks. The upper end of the hook was attached to a tension transducer and the lower end was kept stable. Active tension of 1 to 4 gr, was applied to all of the samples. The vascular rings were suspended under this tension for a minimum of 60 minutes. The samples were kept alive by 37ºC oxygenated Krebs solution baths every 20 minutes. In order to measure the relaxation response, the samples were exposed to phenylephrine (Merck, Turkey) (10 M was reached. The concentration-reponse curves were obtained. The data were transferred to the computer with the help of the Transducer Acquisition System (COMMAT TDA-10-A, COMMAT, Turkey) and was stored as POLWIN97.
Statistical analysis
The statistical analysis of the data was performed by Graphpad Prism 4 Version Demo. The concentration-response curves were also constructed by this program. Nonlinear regression analysis (variable slope) and one way ANOVA were applied to the graphics. A value of p<0.05 represented the statistically significance cut-off value.
Results
The vasodilatation response to dipyridamole was studied in phenyephrine pre-treated graft samples. In the LIMA graft samples, the vasodilatation response to dipyridamole was 43.2%±1.6% at a concentration of 10 -6 M and reached its maximal response (97.6± 4.1) at a concentration of 10 -3.5 M (Figure 1) . In RA graft samples, the vasodilatation response to dipyridamole was 36.3%±1.8% at a concentration of 10 -6 M and was 95.3%± 2.7% at a concentration of 10 -3.5 M (Figure 2) . In SV graft samples, however, the vasodilatation response to dipyridamole was 43.2±1.4% at a concentration of 10 -6 M and was 96.6%±2.2% at a concentration of 10 -3.5 M (Figure 3) . Figure 4 demonstrates the vasodilatation response curves of all three tissue samples reveal the fact that no statistically significant difference exists among the samples, all of which respond with the same amount of vasodilatation.
Discussion
Dipyiridamole, which is a well-known antiplatelet drug, has also been demonstrated to inhibit human and rabbit vascular smooth muscle cell proliferation in vitro. Dipyridamole acts through the metabolism and transport of adenosine by preventing the reuptake of adenosine by erythrocytes and other cells, increasing intravascular adenosine levels and thereby reducing the cyclic adenosine monophosphate (cAMP) intracellularly, causing vasodilatation (5-10). Due to its vasodilatatory feature, it is a widely used drug in coronary and peripheral vascular diseases (11-13).
In patients with CABG, anginal symptoms may recur because of progressive aterosclerosis in the native coronary arteries or occlusion of grafts for various reasons. Dipyridamole stress testing is frequently used in this setting for the evaluation of angina and graft flow (14) (15) (16) (17) . This test studies the grafts in vivo. However, there are no studies conducted to show the effect of dipyridamole on grafts in vitro. We studied the effect of dipyridamole on IMA, RA and SV grafts in a tissue bath system. The pre-constricted samples of IMA, RA and SV grafts dilated by the same amount with dipyridamole. The relaxation response increased directly proportional to increasing concentrations of dipyridamole.
It is well known that trauma or vasospasm of the graft during its collection or preparation unfavourably affects the long term graft patency. Since the use of electrocautery during the collection can disrupt the constriction-relaxation response, we used dissection scissors insead of electrocautery.
Papaverin, diltiazem and nitrogylcerin are widely used to prevent the induction of vasospam during the preparation of the graft (1, 2) . Therefore, we did not use any vasodilatory agent either, in order not to disrupt the constriction-relaxation response of the grafts. (14) , investigated the augmentation of flow rates in IMA and SV grafts by dipyridamole induced stress echocardiography in patients with CABG. They found the same amount of increase with dipyridamole both in SV and IMA grafts. This in vivo experiment is in concordance with our in vitro findings.
Vroom et al. (9) , used phosphodiesterase III enzyme inhibitors and demonstrated vasodilatation in small arteries independent of potassium channels or nitric oxide release. However, we studied both larger sized arteries and veins, where we showed that dipyridamole has the same vasodilatory effects on both.
In conclusion, dipyridamole induced vasodilatation response studied in an in vitro tissue bath system has produced the same amount of vasodilatation in all IMA, RA and SV grafts. 
